Welcome to our dedicated page for Serina Therapeutics SEC filings (Ticker: SER), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Serina Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Serina Therapeutics's regulatory disclosures and financial reporting.
Insider transaction summary (SEC Form 4)
On 07/28/2025, Serina Therapeutics (SER) Chief Scientific Officer Dr. Randall Moreadith exercised 6,500 stock options at a strike of $0.06 and immediately sold the resulting shares in the open market. The weighted-average sale price was $5.89 (price range $6.02–$5.60). Net of the option cost, the insider realized roughly $38 k in gross proceeds, while the company received only ~$390 from the option exercise.
After the transactions the officer now holds 0 common shares directly, but still owns 488,686 fully-vested options expiring 05/06/2031. The divestment is immaterial relative to SER’s share count and does not alter overall insider exposure, yet it removes all direct share ownership for this executive.
No other securities, derivatives or accompanying disclosures were reported.
Form 4 snapshot – Serina Therapeutics (SER): On 07/21/2025 Chief Scientific Officer Randall Moreadith exercised 6,500 fully-vested options at an exercise price of $0.06 and immediately sold the same 6,500 common shares in the open market. The weighted-average sale price was $5.34 (range $5.31-$5.40), generating gross proceeds of roughly $34.7 k and eliminating his direct common-stock position, which now stands at 0 shares. He retains 495,186 options after the transaction. The filing reflects a routine option-exercise-and-sell pattern rather than large-scale disposal, but it does reduce immediate share ownership by a named executive.